AptarGroup, Inc. (ATR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

AptarGroup, Inc. (ATR) Healthcare & Pipeline Overview

AptarGroup, Inc. delivers dispensing, sealing, and active material science solutions across diverse markets, including pharmaceuticals, beauty, and food and beverage. With a focus on innovative packaging and delivery systems, AptarGroup leverages strategic partnerships and a global presence to maintain a competitive edge in the healthcare and consumer goods sectors.

What Is the Investment Thesis for ATR?

With a market capitalization of $7.76B and a P/E ratio of 21.97, the company demonstrates financial stability. A profit margin of 10.0% and a gross margin of 29.0% reflect efficient operations. Key growth catalysts include expanding its presence in the Pharma segment through innovative drug delivery systems and leveraging partnerships for sustainable packaging solutions. Potential risks include fluctuating raw material costs and increasing competition within the dispensing solutions market. The company's beta of 0.44 suggests lower volatility compared to the broader market, making it a noteworthy option for risk-averse investors. The dividend yield of 1.56% provides a steady income stream.

Based on FMP financials and quantitative analysis

ATR Key Highlights

Market Cap of $7.76B indicates substantial investor confidence and market valuation.

• P/E Ratio of 21.97 suggests a reasonable valuation relative to earnings.
• Profit Margin of 10.0% demonstrates solid profitability in a competitive market.
• Gross Margin of 29.0% reflects efficient cost management in manufacturing and distribution.
• Dividend Yield of 1.56% provides a consistent return for shareholders.

Who Are ATR's Competitors?

ATR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ATR's Key Strengths?

Diversified product portfolio across multiple sectors.

• Strong relationships with leading pharmaceutical, beauty, and food and beverage companies.
• Global presence with operations in Asia, Europe, Latin America, and North America.
• Focus on innovation and sustainable solutions.

What Are ATR's Weaknesses?

Exposure to fluctuating raw material costs.

• Dependence on key suppliers for certain components.
• Potential impact from regulatory changes in healthcare and packaging.
• Competition from established players and emerging market entrants.

What Could Drive ATR Stock Higher?

Expansion of Pharma segment through innovative drug delivery systems.

• Launch of new sustainable packaging solutions in partnership with PureCycle Technologies LLC.
• Penetration of emerging markets in Asia and Latin America.
• Development of active material science solutions for enhanced product protection.

What Are the Key Risks for ATR?

Insider selling — insiders were net sellers of roughly $3.8M recently.

• Fluctuations in raw material costs affecting profitability.
• Increasing competition from alternative packaging solutions.
• Regulatory changes in healthcare and packaging impacting product compliance.
• Economic downturns affecting consumer spending on beauty and personal care products.

What Are the Growth Opportunities for ATR?

• Expansion in the Pharma Segment: AptarGroup can capitalize on the growing demand for advanced drug delivery systems, particularly in injectable and respiratory treatments. The global drug delivery market is projected to reach $240 billion by 2028, offering significant growth potential. By developing innovative solutions like metered dose inhaler valves and elastomer components, AptarGroup can strengthen its market position and drive revenue growth. This expansion is expected to contribute significantly to the company's revenue within the next 3-5 years.
• Strategic Partnerships for Sustainable Packaging: Collaborating with companies like PureCycle Technologies LLC allows AptarGroup to develop sustainable packaging solutions using recycled polypropylene. With increasing consumer and regulatory focus on sustainability, this initiative can attract environmentally conscious customers and enhance the company's brand image. The market for sustainable packaging is estimated to reach $440 billion by 2027, providing a substantial growth opportunity for AptarGroup. These partnerships are expected to yield tangible results within the next 2-3 years.
• Penetration of Emerging Markets: Expanding its presence in emerging markets, particularly in Asia and Latin America, can drive significant growth for AptarGroup. These regions are experiencing rapid economic growth and increasing demand for packaged goods and healthcare products. By establishing local manufacturing facilities and distribution networks, AptarGroup can cater to the specific needs of these markets and gain a competitive advantage. This expansion is expected to contribute to long-term revenue growth over the next 5-7 years.
• Innovation in Active Material Science Solutions: Investing in research and development to create active material science solutions can differentiate AptarGroup from its competitors. These solutions can enhance product protection, extend shelf life, and improve consumer experience. By focusing on innovation, AptarGroup can secure patents and establish a technological edge. These innovations are expected to generate new revenue streams within the next 3-4 years.
• Leveraging Digital Health Platforms: Collaborating with companies like Sonmol to develop digital therapies and services platforms can enhance AptarGroup's offerings in the healthcare sector. These platforms can improve patient adherence, monitor treatment outcomes, and provide personalized healthcare solutions. The digital health market is experiencing rapid growth, with a projected value of $660 billion by 2025. By integrating its dispensing solutions with digital health platforms, AptarGroup can create a comprehensive ecosystem and drive value for its customers. This integration is expected to yield significant results within the next 2-3 years.

What Are ATR's Competitive Advantages?

• Proprietary Technology: AptarGroup's patented dispensing and sealing technologies create a barrier to entry for competitors.
• Established Customer Relationships: Long-standing relationships with major pharmaceutical, beauty, and food and beverage companies provide a stable revenue base.
• Diversified Market Segments: Operating across multiple sectors reduces reliance on any single market, mitigating risk.
• Global Presence: A wide geographic footprint allows AptarGroup to serve customers worldwide and capitalize on growth opportunities in emerging markets.

What Does ATR Do?

AptarGroup, Inc., incorporated in 1992 and headquartered in Crystal Lake, Illinois, is a global leader in providing a wide range of dispensing, sealing, and material science solutions. The company operates through three primary segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment offers pumps for nasal allergy treatments, metered dose inhaler valves for respiratory ailments, elastomer components for injectable primary packaging, and active material science solutions. The Beauty + Home segment provides pumps, closures, aerosol valves, accessories, and sealing solutions for the personal care, home care, and beauty markets. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup sells its products through its own sales force and via independent representatives and distributors across Asia, Europe, Latin America, and North America. The company has established strategic partnerships, including collaborations with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene for dispensing applications and with Sonmol to develop a digital therapies and services platform targeting respiratory and other diseases. AptarGroup's solutions are integral to enhancing product functionality, consumer experience, and supply chain efficiency for its diverse customer base.

What Products and Services Does ATR Offer?

• Provides dispensing solutions for nasal allergy treatments.
• Manufactures metered dose inhaler valves for respiratory ailments.
• Offers elastomer components for injectable primary packaging.
• Develops active material science solutions.
• Supplies pumps, closures, and aerosol valves for personal and home care markets.
• Provides dispensing and non-dispensing closures for the food and beverage markets.
• Offers spray pumps and aerosol valves to the food and beverage industries.

How Does ATR Make Money?

• Manufactures and sells dispensing, sealing, and material science solutions.
• Operates through three segments: Pharma, Beauty + Home, and Food + Beverage.
• Generates revenue through direct sales and distribution networks.
• Focuses on innovation and strategic partnerships to enhance product offerings.

What Industry Does ATR Operate In?

AptarGroup, Inc. operates within the medical instruments and supplies industry, which is experiencing growth driven by increasing healthcare expenditure and demand for advanced drug delivery systems. The market is competitive, with key players focusing on innovation and strategic partnerships. AptarGroup's focus on dispensing, sealing, and material science solutions positions it well to capitalize on the increasing demand for specialized packaging and delivery systems in the pharmaceutical, beauty, and food and beverage sectors. Competitors include GMED: Globus Medical, Inc., MOH: Molina Healthcare, Inc., MASI: Masimo Corporation, HSIC: Henry Schein, Inc., and HALO: Halozyme Therapeutics, Inc.

Who Are ATR's Key Customers?

• Pharmaceutical companies requiring drug delivery systems.
• Beauty and personal care brands needing dispensing and packaging solutions.
• Home care product manufacturers utilizing closures and aerosol valves.
• Food and beverage companies requiring dispensing and non-dispensing closures.

How AptarGroup, Inc. Is Valued

AptarGroup, Inc. carries a market capitalization of $7.76B, placing it in the mid-cap category. Analyst price targets span from $160.00 to $160.00, with a consensus of $160.00. At the current price of $121.64, that implies approximately 32% upside potential. Relative to its peer group, ATR's quantitative score of 75/100 is roughly in line with the peer average of 71/100.

Company Profile

AptarGroup, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Crystal Lake, US. The company is led by CEO Gael Touya. ATR has traded publicly since 1993.

Return on equity for AptarGroup, Inc. stands at 14.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.6%, showing how much profit it generates from its asset base. ATR trades at a trailing price-to-earnings ratio of 21.97, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.2%, the inverse of the P/E and a quick read on earnings relative to price.

AptarGroup, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.90 places it in the safe zone, indicating low near-term bankruptcy risk.

AptarGroup, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 5.6% above estimates on average.

Wall Street analysts project AptarGroup, Inc. revenue of about $3.98B for fiscal 2026, with EPS near $5.52. The estimate reflects 7 contributing analysts.

Over the past six months, AptarGroup, Inc. insiders filed 29 SEC Form 4 transactions — 15 sales and 14 purchases. On net that is roughly 23K shares disposed (about $3.8M), a signal worth weighing alongside the fundamentals.

ATR Financials

ATR Latest News

ATR Analyst Consensus

ATR MoonshotScore

Latest AptarGroup, Inc. Analysis

What Investors Ask About AptarGroup, Inc. (ATR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources